Abstract: A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressing comprising the materials, methods of treatment with the materials, and methods of making the materials.

Abstract: Disclosed is a biocompatible, hemostatic, cross-linked gelatin composition comprising a biocompatible material comprising cross-linked gelatin and a sufficient amount of wetting agent to permit uniform wetting of the sponge in the presence of an aqueous solution.

Abstract: A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.

Abstract: Methods, system and compositions for making and using a bioresorbable linked dressing made of bioresorbable microspheres in various configurations are provided for use in applying reduced pressure to a wound site. The methods include manufacture of a bioresorbable dressing comprising a casing and bioresorbable microspheres in the form of a rope shape. Further, the casing of the dressing comprises pores formed by a porogen system that may be activated by external to the wound or formed in situ within the wound site. The shape of the dressing allows the dressing to be placed into the wound site such that it fills the shape and size of the wound. Embodiments include formation of various rope dressing and their use in conjunction with reduced pressure therapy.

Abstract: A body shaped wound dressing wherein the dressing is a knitted or woven garment comprising a cellulosic yarn, which garment has been carboxymethylated at least in parts of its wound contacting surface.

Abstract: The present application is drawn to a synthetic, polymer hydrogel-based material, which is able to actively induce the body's natural hemostatic coagulation process in blood or acellular plasma. The present invention provides the development of a primary amine containing polymer hydrogel capable of inducing blood coagulation and delivering therapeutics for hemostatic or wound care applications, and a method of forming such a primary amine containing polymer hydrogel capable of inducing the blood coagulation process. The primary amine containing polymer hydrogel is able to achieve the same end result as biological-based hemostatics, without the innate risk of disease transmission or immunological response, and at a fraction of the price. Furthermore, due to its inherent hydrogel-based design the material has the capability of arresting blood loss while simultaneously delivering therapeutics in a controlled manner, potentially revolutionizing the way in which wounds are treated.

Abstract: Provided are articles containing a solid surface material with an antimicrobial agent in a thermoset and/or thermoplastic resin matrix, wherein the antimicrobial agent comprises a chitosan-metal complex.

Abstract: A wound dressing and a method for enhancing the clotting comprising a plurality of hydrophilic microfibers bonded to each other to form a mat with the plurality of microfibers having a pore size sufficiently small to inhibit wicking platelets from a wound into the microfibers so that when applied to a wound the blood coagulates and the microfibers remain external to the wound.

Abstract: A therapeutic device for promoting the healing of a wound in a mammal is disclosed. An exemplary device comprises a permeable structure having a plurality of depressions formed in a surface thereof. In use, the surface having the depressions is disposed adjacent a surface of the wound. A method of treating a wound comprises the steps of providing a permeable structure comprising a plurality of randomly disposed fibers and having i) a plurality of wound surface contact elements disposed between end portions of the structure, and ii) a plurality of voids defined by the contact elements; and applying the permeable structure to at least one surface of the wound.

Abstract: A method for the topical treatment of skin aging and acne and the improvement of skin appearance is disclosed. Compositions for use in this method and a kit containing such compositions are also disclosed. In some of the embodiments of the invention, either one, or both, of the acid composition and neutralizing composition useful in the method for the topical treatment of skin aging and acne and the improvement of skin appearance are of low viscosity. The compositions and methods are effective but gentle enough to be suitable for daily home use by the consumer.

Abstract: The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to achieve hemostasis at an increased rate. More specifically the present invention relates to hemostatic compositions that achieve a hemostatic effect at a distance from the site of application of the composition, and a method for administering such a composition to effectively reduce localized vascular complications associated with treating a breach or puncture in a vein or artery and reduce the time to achieve hemostasis.

Abstract: A device for promoting the clotting of blood comprises a clay material in particle form and a receptacle for containing the clay material. At least a portion of the receptacle is defined by a mesh. Another device comprises a gauze substrate and a clay material disposed on the gauze substrate. Another device is a bandage comprising a substrate, a mesh mounted on the substrate, and particles of a clay material retained in the mesh. A hemostatic sponge comprises a substrate, a hemostatic material disposed on a first surface of the substrate, and a release agent disposed on a second surface of the substrate. The release agent is disposed on the wound-contacting surface of the substrate. When treating a bleeding wound, application of the hemostatic sponge causes at least a portion of the hemostatic material to come into contact with blood through the release agent and through the substrate.

Abstract: The invention provides effervescent composition comprising a bisphosphonate, an acidic compound, an alkaline effervescing component, and optionally an anti-ulcer agent and methods of treating osteoporosis in a mammal using the effervescent compositions.

Abstract: Assemblies for the adhesive attachment to the skin or mucosa of a host are disclosed. The assembly or transdermal patch includes an outer backing layer, a first layer of adhesive on the inner surface of the outer backing layer, an inner backing layer, and an intermediate release liner between the first layer of adhesive and the inner backing layer. The intermediate release liner includes a releasable surface on both its inner and outer surfaces.

Abstract: An anti-adhesion wound barrier fabricated from amnion obtained from human birth tissue and treated with a glutaraldehyde solution is provided. The amnion is treated in 1% glutaraldehyde solution for up to 15 minutes to fix the amnion. Methods of processing the birth tissue to prepare the amnion for use as a wound barrier are also provided. Use of the amnion anti-adhesion wound barrier for dressing wounds is also described.

Abstract: Compositions are provided that contain a TRPV1 agonist, such as capsaicin, and a solvent system. Topical application of the composition results in rapid delivery of agonist to the dermis and epidermis. Method of using the compositions for reducing nociceptive nerve fiber function in subjects, and for treatment of capsaicin-responsive conditions are also provided.

Abstract: A formulation made from natural substances, for healing cuts, bruises, wounds, and the like on the skin, has a natural-heal compound that has proportion of very fine curcuma longa (turmeric) powder, lavender essential oil, and glycerol that is compounded to the consistency of a paste. The formulation has ? teaspoon to ? teaspoon of very fine turmeric powder, one to three drops of lavender essential oil, and one-half to one and one-half drop of glycerol for a per square inch of the wound area. The formulation is used in a first aid means using a bandage, and as cotton gauze that is sealed in an air tight package.

Abstract: Compositions and methods for treating angiogenesis-related diseases and for skin care in mammals is disclosed that includes, as an active pharmaceutical agent, an effective amount of purified extract from Angelica sinensis, or a fraction or a lyophilizate thereof, or one or more active component contained in said extract.

Abstract: Novel phosphate starch derivatives are useful in wound healing. Novel phosphorylated cottons are useful in wound healing. Silver-derivatized wound care products are provided which survive washing and remain part of the wound care product. Silver-derivatized wound care products are provided that have favorable elastase-sequestering activity while advantageously appearing white-colored, without needing to darken to grey or black as usually would occur when working with silver. Also, starch products with outstanding water uptake are provided.

Abstract: In one embodiment, a method for preparing a selectively releasable adhesive includes condensing a multifunctional alcohol and a multifunctional carboxylic acid to form a prepolymer and curing the prepolymer at an elevated temperature and a vacuum to produce a cured polymer.

Abstract: In one embodiment, an article incorporating a selectively-releasable adhesive includes a substrate having a surface and a layer of selectively-releasable adhesive provided on the surface of the substrate, the selectively-releasable adhesive comprising a copolymer formed from a multifunctional alcohol and a multifunctional carboxylic acid that has been cured.

Abstract: A therapeutic device for promoting the healing of a wound in a mammal is disclosed. An exemplary device comprises a permeable structure having a plurality of depressions formed in a surface thereof. In use, the surface having the depressions is disposed adjacent a surface of the wound. A method of treating a wound comprises the steps of providing a permeable structure comprising a plurality of randomly disposed fibers and having i) a plurality of wound surface contact elements disposed between end portions of the structure, and ii) a plurality of voids defined by the contact elements; and applying the permeable structure to at least one surface of the wound.

Abstract: An article is applied to the body of an animal (including humans) to provide both absorbency and antimicrobial activity. The article may comprise a water absorbent material; and a composition that reacts with water to produce molecular iodine. The composition provides a local concentration (in the water) of at least 10 parts per million iodine in water carried by the material (that is actual water supported by the water absorbent material) when the material has 5% by weight of water present in the water absorbent. The article may be a diaper, sanitary pad, bandage, bandaid or wrap for an animal.

Abstract: A neovascularization promoting composition, a granulation formation-promoting composition and a preventive or curative composition for skin ulcer, comprising a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain thereof. The provided compositions of the present invention are useful as a drug capable of promoting granulation formation and neovascularization and being effective in tissue restoration, especially as a preventive and curative agent for skin ulcer.

Abstract: A method for applying pressure to skin with a dressing. The method including adhering at least a portion of the dressing to the skin and changing the shape of the dressing after application of the dressing to the skin wherein the changed shape applies pressure to the skin. The changing can include releasing a member from the dressing to allow the dressing to change the shape of the dressing; deforming at least a portion of the dressing to change the shape of the dressing or allowing the dressing to heat to above a transition temperature at which the dressing changes shape.

Abstract: The present invention relates to improved yellow iron oxide pigments and to their use.

Abstract: A wound dressing includes one or more layers containing a first anti-microbial agent and/or at least one zinc-containing agent.

Abstract: A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.

Abstract: A wound dressing (500) includes a flexible layer of material (501) that is treated with an antimicrobial agent (604), such as PHMB. The antimicrobial agent (604) ionically bonds to cellulose fibers (502) of the flexible layer of material (501) through a bonding agent (601). The bonding agent (601) increases the number of available carboxylate bonding groups beyond a characteristic carboxylate bonding group density normally associated with untreated cellulose fiber such that more antimicrobial agent (604) can be bonded to the flexible layer of material (501). An optional antifungal agent (606) can also be applied to the flexible layer of material (501).

Abstract: Morpholino compounds of Formula (I) wherein R1 is a straight or branched alkyl group containing 8 to 16 carbon atoms at the 2- or 3-position of the morpholino ring, and R2 is a straight or branched alkyl group containing 2 to 10 carbon atoms, substituted with a hydroxy group except in the alpha-position, or pharmaceutically acceptable salts thereof, have been found to be surprisingly effective at promoting the healing of a wound.

Abstract: A wound dressing includes one or more layers containing a first anti-microbial agent and at least one of: a chelating agent, and a second anti-microbial agent.

Abstract: The present invention provides a topical composition comprising (i) an amount of an AP-1 signaling inhibitor sufficient to reduce, delay or prevent apoptosis and/or necrosis induced by dermal wounding and/or to induce and/or enhance proliferation of a cell; and (ii) a suitable carrier or excipient e.g., a topical carrier or excipient or other carrier or excipient for dermal application. For example, the AP-1 signaling inhibitor is a peptide analog comprising the sequence set forth in SEQ ID NO: 104. The present invention also provides a method of treating a dermal wound comprising topically administering said topical composition to a subject suffering from a dermal wound.

Abstract: In one embodiment, a selectively-releasable adhesive includes a copolymer formed from a multifunctional alcohol and a multifunctional carboxylic acid, wherein the copolymer has been cured the equivalent of up to approximately 20 hours at 120° C. and 100 millitorr.

Abstract: Methods for improved treatment of wounds on a patient. Method includes locally administering a healing composition to the skin wound such that the healing of the skin wound is enhanced. The healing composition includes from about 5 mg to about 40 mg lidocaine hydrochloride per gram of the healing composition, from about 250 units to about 2000 units polymyxin B sulfate per gram of the healing composition, and from about 10 units to about 100 units bacitracin zinc per gram of the healing composition.

Abstract: The invention relates to a wound dressing comprising a microbial-derived cellulose for treatment of specific types of chronic wounds, including pressure sores, venous and diabetic ulcers. The wound dressing is capable of donating liquid to dry substances is also capable of absorbing exudating wounds.

Abstract: Various embodiments are directed to multi-functional wound-care dressing matrices that can protect and promote new tissue growth at a wound site. The multi-functional wound care matrix can incorporate polyphosphazenes of formula I, as a component that can be configured into various forms, including as fibrous mats, porous membranes, nonporous films, particulate formulations, and equivalents. The multi-functional wound-care dressing matrix of the present disclosure exhibit high-performance properties conferred by polyphosphazenes of formula I. Exceptional biocompatible properties of polyphosphazenes of formula I provide an ideal tissue-contacting surface for the multi-functional wound-care dressing matrix of interest.

Abstract: Described herein is a transmucosal delivery device and their use for delivering bioactive agents across a mucosal membrane. The delivery devices contain a pharmaceutically acceptable oxidizing and agents that facilitates the delivery of the blood stream across the mucosal membrane.

Abstract: A method of treating a superficial or partial thickness burn caused by heat, or by UV or laser radiation is disclosed. The method includes topically applying a topical composition containing an avermectin compound to an affected area immediately after a burn occurs. The method further includes cooling the affected area with ice or water prior to application of the topical composition. Additionally, the method includes topically applying a second topical composition containing fluocinonide and salicylic acid on the affected area to further enhance anti-inflammatory effect of the avermectin compound on the damaged skin.

Abstract: A silk protein membrane is described which is loaded with an antimicrobial compound and has a substantially non-granular ultrastructure which is (i) substantially devoid of micellar silk fibroin substructures and (ii) substantially devoid of pores when analysed by scanning electron microscopy at 0.2 ?m resolution. The antimicrobial compound comprises, in one aspect of the invention, a host defense peptide. The silk protein membrane of the invention can be used in a method for the treatment of wounds and allows the wound dressing to be kept in place after removal of that wound dressing from a wound the wound has less than 105 colony forming units per gram. A method for manufacturing a wound dressing is also disclosed which comprises transferring a cast precursor material and optionally a host defense peptide, into a solid support and then drying the precursor material on the solid support to form a silk protein membrane for use as the wound dressing.

Abstract: A substrate comprising a nonwoven layer containing an ionically crosslinked polymer can be used to control the release of active ingredients. The substrate can be a melamine foam and contain a surfactant and an alginate polymer crosslinked with calcium.

Abstract: Adhesive patches for the transdermal administration of granisetron, comprise an acrylic adhesive containing non-acidic nucleophilic moieties which substantially increase flux of granisetron across the skin.

Abstract: A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.

Abstract: Abrasive compositions which include bioactive materials, such as bioactive glass and bioactive ceramics, which provide biological properties such as anti-inflammatory, anti-microbial, anti-oxidant effects, improved wound healing, and/or other beneficial effects are provided. Also provided are abrasive compositions comprising relatively non-toxic, bioinert glasses and ceramics which provide good abrasive effects, reduce or eliminate potentially harmful small particles; reduce or eliminate clogging of dermabrasion equipment; possess a relatively large surface area for applying coatings; and may be inexpensive and simple to make. Methods for abrading human or animal tissue, such as human skin, by contacting such tissue with these abrasive compositions is also provided.

Abstract: A device for promoting the clotting of blood comprises a clay material in particle form and a receptacle for containing the clay material. At least a portion of the receptacle is defined by a mesh. Another device comprises a gauze substrate and a clay material disposed on the gauze substrate. Another device is a bandage comprising a substrate, a mesh mounted on the substrate, and particles of a clay material retained in the mesh. A hemostatic sponge comprises a substrate, a hemostatic material disposed on a first surface of the substrate, and a release agent disposed on a second surface of the substrate. The release agent is disposed on the wound-contacting surface of the substrate. When treating a bleeding wound, application of the hemostatic sponge causes at least a portion of the hemostatic material to come into contact with blood through the release agent and through the substrate.

Abstract: One aspect of the present invention is directed to antimicrobial surfaces comprised of hydrocarbon polymers with significant hydrophobic character which also contain an amino group with a pKa greater than or equal to about 8. In certain embodiments initiated chemical vapor deposition (iCVD) is used to coat a surface with an antimicrobial polymer.

Abstract: The present invention relates to hemostatic fabric materials, and to the methods for making and using such materials. In particular, the present invention relates to hemostatic fabric materials made from chemically treated cellulose, where the hemostatic material can be soluble on wound surfaces.

Abstract: An occlusive wound dressing for application to wound sites to accelerate the healing process and improve the appearance of the final mature scar including a silicone gel sheet and antimicrobial silver disposed in the silicone gel sheet where the silver may be present in the form of particles or wires and the particles or wires may be disposed in the silicone gel sheet in a grid pattern or as a lattice, and an adhesive may be present on at least one face of the silicone gel sheet. The adhesive may be present in the form of spaced lines with adhesive-free areas between the lines containing the antimicrobial silver. It is preferred that an antibruising agent is also included in the silicone gel.

Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an addition two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.

Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphinein accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.

Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.